Intervention not reported
Mortality (deaths during trial period) · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
It is very uncertain whether the intervention changes mortality (deaths during trial period) (very low certainty).
1 finding from 1 review
Intervention not reported
Carriage of NTHi Not meta‐analysed · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Antibiotic prescriptions (number of courses/person/year) **Corticosteroids not meta‐analysed · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
The intervention may leads to higher antibiotic prescriptions (number of courses/person/year)… (low certainty).
1 finding from 1 review
Intervention not reported
Hospital admissions (number of participants hospitalised during trial period) · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Intervention not reported
Adverse events (number of adverse events/person/year) · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
The intervention showed no clear difference in adverse events (number of adverse events/person/year) (low certainty).
1 finding from 1 review
Intervention not reported
Quality of life Not meta‐analysed · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Clinical cure · participants with confirmed toenail onychomycosis
Azole probably leads to lower clinical cure compared with terbinafine (moderate certainty).
1 finding from 1 review
Quality of life · participants with confirmed toenail onychomycosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical cure · participants with confirmed toenail onychomycosis
Azole leads to higher clinical cure compared with placebo (high certainty).
1 finding from 1 review
Mycological cure · participants with confirmed toenail onychomycosis
Azole leads to higher mycological cure compared with placebo (high certainty).
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Azole showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Recurrence · participants with confirmed toenail onychomycosis
Azole showed no clear difference in recurrence rate compared with placebo (low certainty).
1 finding from 1 review
Quality of life · participants with confirmed toenail onychomycosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical cure · participants with confirmed toenail onychomycosis
Griseofulvin showed no clear difference in clinical cure compared with azole (moderate certainty).
1 finding from 1 review
Mycological cure · participants with confirmed toenail onychomycosis
Griseofulvin showed no clear difference in mycological cure compared with azole (moderate certainty).
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Griseofulvin probably leads to higher adverse events compared with azole (moderate certainty).
1 finding from 1 review
Recurrence · participants with confirmed toenail onychomycosis
It is very uncertain whether griseofulvin changes recurrence rate compared with azole (very low certainty).
1 finding from 1 review
RR 4 [0.26, 61.76]
1 study · 7 participants
Very low
Mycological cure · participants with confirmed toenail onychomycosis
Azole probably leads to lower mycological cure compared with terbinafine (moderate certainty).
1 finding from 1 review
Quality of life · participants with confirmed toenail onychomycosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical cure · participants with confirmed toenail onychomycosis
Griseofulvin may leads to lower clinical cure compared with terbinafine (low certainty).
1 finding from 1 review